Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry

MOORESVILLE, N.C., Jan. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec^® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona. Biohaven joins Eurasia Motorsports and BAM Motorsports Management as the primary partner for the premier event. The 24-hour sports car endurance race is held annually at Daytona International Speedway in Daytona Beach, Florida, and is the first major automobile race of the year. Former Daytona 500 Champion Austin Dillon, and 2019-2020 Asian Le Mans Series Champion, Cody Ware, will join the team as drivers for the race.

Rick Ware, former driver and current team owner commented, "We are really excited to join the field for the 24 Hours of Daytona this year. This is just another step in the storied history of this organization, and we are hoping for a great run at the end of next month."

The 24 Hours of Daytona is run on a 3.56-mile (5.73 km) combined road course, utilizing portions of the NASCAR tri-oval and an infield road course. Since its inception, it has been held on the last weekend of January or first weekend of February as part of Speedweeks, and is the first race of the season for the WeatherTech SportsCar Championship. The schedule of events includes the Roar Before the Rolex 24, January 22-24; BMW Endurance Challenge, January 29; and Rolex 24 At Daytona, January 30-31.

Vlad Coric, MD, Chief Executive Officer of Biohaven stated, "Speed and endurance are two words that describe the rapid onset of action and lasting effect when patients consider treatment options for relief from their migraine attacks. Being a part of the 24 Hours of Daytona is another first for us as we continue to support innovative programs to drive awareness of migraine disease and the importance of acute treatment."

Nearly 40 million people in the U.S. suffer from migraine and the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).

Nurtec ODT was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in February 2020 and is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT). A single dose of Nurtec ODT has been shown to get people with migraine back to normal functioning within 60 minutes and have lasting effects for up to 48 hours.

"I am excited to be back behind the wheel of a Ligier LMP2 car," commented Cody Ware. "We had a lot of success overseas in the Asian Le Mans Series, and created some great relationships with other teams, like Eurasia Motorsports. I can't wait to co-pilot the No. 51 Nurtec ODT car in the 24 Hours of Daytona at Daytona International Speedway in January."

"My family and I have had a lot of special moments at Daytona International Speedway so I'm thrilled to be able to add to those memories with my first sports car endurance race in the 24 Hours of Daytona," said Austin Dillon, the 2018 Daytona 500 Champion and a fulltime driver in the NASCAR Cup Series for Richard Childress Racing. "Thank you to Rick Ware and everyone on the Nurtec ODT team for the opportunity to get my Daytona Speedweeks started early this year. I'm looking forward to the solid competition in the WeatherTech SportsCar Championship and doing some road course racing this January."

For additional information on Nurtec ODT, visit www.nurtec.com. Follow Rick Ware Racing, by visiting www.wareracing.com, and be sure to follow along on social media (Facebook, Twitter and/or Instagram). 

About Rick Ware Racing
With a rich and extensive history, Rick Ware Racing has been part of the racing fabric in the USA for over 30 years. The team has recently competed in both Prototypes and the NASCAR Cup Series. The team most recently claimed the 2020 Asian Le Mans Series Am Championship.

About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

About NURTEC ODT
NURTEC^® ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily. For more information about NURTEC ODT, visit www.nurtec.com. 

Indication
NURTEC^® ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use
NURTEC ODT is not indicated for the preventive treatment of migraine.

Important Safety Information
Contraindications: Hypersensitivity to NURTEC ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration. 

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received NURTEC ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with NURTEC ODT.

Drug Interactions: Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of NURTEC ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations:
Pregnant/breast feeding: It is not known if NURTEC ODT can harm an unborn baby or if it passes into breast milk.   
Hepatic impairment: Avoid use of NURTEC ODT in persons with severe hepatic impairment.   
Renal impairment: Avoid use in patients with end-stage renal disease.

Please click here for full Prescribing Information.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Biohaven at 1-833-4Nurtec. 

Please click here for full Prescribing Information and Patient Information.

NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC. 

Biohaven Contact:
Vlad Coric, M.D.
Chief Executive Officer
[email protected] 

Media Contact:
Mike Beyer
Sam Brown Inc.
[email protected]
312-961-2502 

Rick Ware Racing Contact:
Kate Fegley
[email protected]

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

Related Links

http://biohavenpharma.com